Status:
ACTIVE_NOT_RECRUITING
Heart Failure and Preserved Ejection Fraction: Observation of Its Progression and Prognosis (HOPP-BERN)
Lead Sponsor:
Insel Gruppe AG, University Hospital Bern
Conditions:
Heart Failure With Preserved Ejection Fraction
Eligibility:
All Genders
18+ years
Brief Summary
Analysis of longitudinal data, cardiovascular magnetic resonance (CMR) imaging and health related data, of patients with heart failure and preserved ejection fraction (HFpEF) over a timeframe of 5 yea...
Detailed Description
Heart Failure with Preserved Ejection Fraction (HFpEF) is becoming increasingly prevalent, yet diagnostics, characterization and prognosis of the disease is still uncertain. Multiple contributing fact...
Eligibility Criteria
Inclusion
- Known Heart Failure with Preserved Ejection Fraction (HFpEF) (based on invasive measurement) or high probability of HFpEF (\>70% based on H2FPEF score ≥4)
- Ability to provide informed consent (knowledge of project languages), \>18 years
Exclusion
- MRI incompatibility (ie. pacemakers, ICD, internal defibrillators)
- Acute myocardial infarction (\<90 days)
- Recent cardiovascular surgery or intervention (\<90 days)
- Severe valve disease
- Known infiltrative diseases (i.e. amyloidosis, sarcoidosis)
- Known hypertrophic cardiomyopathy)
- ARVC (arrhythmogenic right ventricular cardiomyopathy), non-compaction cardiomyopathy
- Heart transplant
- Treatment for chemotherapy or radiotherapy
- Pregnancy
Key Trial Info
Start Date :
March 2 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2029
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT04395846
Start Date
March 2 2020
End Date
December 31 2029
Last Update
May 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Inselspital, Bern University Hospital
Bern, Switzerland, 3010